Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback